High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer,Urologic Oncology: Seminars and Original Investigations

当前位置： X-MOL 学术 › Urol. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer
Urologic Oncology: Seminars and Original Investigations ( IF 2.4 ) Pub Date : 2021-07-28 , DOI: 10.1016/j.urolonc.2021.06.021
Danijel Sikic ₁ , Markus Eckstein ₂ , Veronika Weyerer ₂ , Jennifer Kubon ₁ , Johannes Breyer ₃ , Florian Roghmann ₄ , Frank Kunath ₁ , Bastian Keck ₁ , Philipp Erben ₅ , Arndt Hartmann ₂ , Ralph M Wirtz ₆ , Bernd Wullich ₁ , Helge Taubert ₁ , Sven Wach ₁

Affiliation

Introduction

Molecular markers associated with breast cancer are assumed to be associated with outcome in non-muscle-invasive bladder cancer (NMIBC).

Materials and methods

We retrospectively investigated the association of the mRNA expression of estrogen receptor 1 (ESR1) and 2 (ESR2), progesterone receptor (PGR), MKI67, and HER2 (ERBB2) with recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS) in 80 patients with stage T1 NMIBC.

Results

High expression of ESR2 (P = 0.003), ERBB2 (P < 0.001), and MKI67 (P = 0.029) was associated with shorter RFS. Only high ERBB2 was an independent prognostic factor for reduced RFS (HR = 2.98; P = 0.009). When sub stratifying the cohort, high ESR2 was associated with reduced RFS (P < 0.001), CSS (P = 0.037) and OS (P = 0.006) in patients without instillation therapy. High ESR2 was associated with reduced CSS (P = 0.018) and OS (P = 0.029) in females and with shorter RFS in both sexes (males: P = 0.035; females: P = 0.010). Patients with high ERBB2 showed reduced CSS (P = 0.011) and OS (P = 0.042) in females and reduced CSS (P = 0.012) in those without instillation, while RFS was significantly reduced irrespective of sex or instillation.

Conclusion

High mRNA expression of ERBB2 is an independent predictor of reduced RFS in patients with stage T1 NMIBC. High ERBB2 and ESR2 are associated with reduced outcomes, especially in females and patients without instillation therapy.

中文翻译：

ERBB2的高表达是T1期非肌层浸润性膀胱癌患者无复发生存期降低的独立危险因素

介绍

假设与乳腺癌相关的分子标志物与非肌肉浸润性膀胱癌 (NMIBC) 的结果相关。

材料和方法

我们回顾性研究了雌激素受体 1 (ESR1) 和 2 (ESR2)、孕激素受体 (PGR)、MKI67 和 HER2 (ERBB2) 的 mRNA 表达与无复发 (RFS)、癌症特异性 (CSS)、 80 名 T1 期 NMIBC 患者的总生存期 (OS)。

结果

ESR2 ( P  = 0.003)、ERBB2 ( P < 0.001) 和 MKI67 ( P  = 0.029) 的高表达与较短的 RFS 相关。只有高 ERBB2 是 RFS 降低的独立预后因素（HR = 2.98；P  = 0.009）。当对队列进行亚分层时，高 ESR2 与 未接受滴注治疗的患者的 RFS ( P < 0.001)、CSS ( P  = 0.037) 和 OS ( P = 0.006) 降低相关。高 ESR2 与女性的 CSS ( P  = 0.018) 和 OS ( P  = 0.029) 降低以及两性的 RFS 较短相关（男性：P  = 0.035；女性：P = 0.010)。ERBB2 高的患者在女性中表现出 CSS ( P  = 0.011) 和 OS ( P  = 0.042) 降低，在未滴注的患者中 CSS ( P  = 0.012) 降低，而无论性别或滴注如何，RFS 均显着降低。